Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Solid Biosciences Inc.SLDB · Entity 4915 | Director | June 10, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Solid Biosciences Inc.
Report date June 10, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.61 · Expires 2036-06-10 | Direct | 77,500 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 77,500 · Balance 77,500 F1: This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 25, 2018 Filed Jul 26, 2018 22:52 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 193,000 | $0.00 Strike: $37.89 | $0.00 |
DisclosureSEC source: 0000899243-18-020707 · doc4.xml · derivative · entry 1 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,000 Underlying: Common Stock · 193,000 shares Expires 2028-07-25 F1 · derivative.exercise_date: This option was granted on July 25, 2018 and vests in four equal annual installments on the anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.